Glycogen storage disease type II

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
A Gastroenterology (ATC A) 2
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase III: 1 Phase IV: 1 Phase I (First in Human): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    AVALGLUCOSIDASE ALFA
    2024-513859-33-00 5 countries 2022 n=8
    Ended

Phase IV

1 trial
  • Sanofi Winthrop Industrie Commercial
    AVALGLUCOSIDASE ALFA
    2024-514773-22-00 1 country 2022 n=18
    Ended

Phase I (First in Human)

1 trial
  • Genentech Inc. Commercial
    VANGLUSAGENE ENSIPARVOVEC
    2023-509303-32-00 1 country 2021 n=2 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase III 0
Sanofi Winthrop Industrie Commercial 1 Phase IV 0
Genentech Inc. Commercial 1 Phase I (First in Human) 1
New trials by year
2021
1
2022
2
← All indication landscapes